Medical Devices

PathAI's PathAssist Derm receives FDA Breakthrough designation, promising to enhance accuracy and speed in diagnosing the most common cancer in the U.S.

A new partnership gives thousands of young athletes in Las Vegas free recovery tech while a unique manufacturing model boosts the local economy.

With its pivotal trial fully enrolled, Liberate Medical’s VentFree device aims to shorten ICU stays, reduce complications, and cut healthcare costs.

From the surface of Mars to Earth's most advanced labs, space-tested positioning tech is enabling breakthroughs in semiconductors, photonics, and biotech.

A novel sputum test could end the trial-and-error approach for millions with chronic respiratory disease, promising a new era of personalized medicine.

A new deal brings Nanox's low-radiation, cost-effective Nanox.ARC to orthopedic clinics, aiming to reshape point-of-care diagnostics in the region.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.

A novel inhaled RNA therapy for a specific group of cystic fibrosis patients gains EMA fast-track status, promising accelerated access to new treatment.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

New research reveals a media blind spot for hearing loss, fueling stigma. A new campaign aims to change the picture and normalize hearing aids for millions.

Esperion's $75M+ deal for Corstasis and its novel nasal diuretic, Enbumyst, targets a $4B market and a new era of at-home edema management.

With 74,000 UK mothers losing jobs annually, a new alliance between Momcozy and AllBright uses tech and advocacy to turn the motherhood penalty into power.

At ECR 2026, Subtle Medical showcases AI that boosts existing scanners, expands into CT, and promises faster, clearer diagnostics for patients.

Greenwich LifeSciences' Phase III trial for its GLSI-100 immunotherapy is enrolling patients faster than ever, with early data echoing past success.

A €21.5M consortium is launching clinical trials for AI that assists in brain and cancer surgery, aiming to ease a critical European doctor shortage.

A novel CRISPR-based therapy safely targets deadly E. coli in the gut, showing promise in the fight against antibiotic resistance and for protecting cancer patients.

A 2.5-year-old's sudden paralysis led to a high-risk, pioneering neuro-intervention that reversed a severe stroke, setting a new benchmark for pediatric care.

With soaring revenue and new EU approval, Senseonics is taking control of its sales, but rising costs raise questions about its path to profitability.

Entrepreneur Daniel Gestetner discusses resilience, a $1B exit, and why true success isn't about winning at all costs in a revealing new podcast.